This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Oct 2020

Recipharm’s proprietary molecule Erdosteine has been positively tested as part of COVID-19 treatment

Recipharm is pleased to announce that the results of the study with Erdosteine as an add-on treatment for COVID-19 patients are now available.

The clinical study involved 20 patients affected by COVID-19 with severe respiratory failure, hospitalized in one of the major COVID-19 centres of Milan, in Lombardy, the Italian region mostly affected by SARS-CoV-2.

The study indicates that patients taking Erdosteine after hospital discharge benefit from significant improvements in health-related quality of life parameters (HRQoL) and dyspnoea. This study is the first to report HRQoL details in patients with COVID-19.

Full study outcomes have been recently published on the peer-reviewed journal Multidisciplinary Respiratory Medicine (Vol. 15, 2020, 713; This study opens up new perspectives for the use of Erdosteine in COVID-19 patients, most likely due to its multiple mechanism of action (antioxidant, mucoactive, anti-inflammatory, antibiotic enhancer) and its ability to increase the endogenous levels of Glutathione. This may have blocked the spreading of the virus in the lungs giving a faster recovery to patients treated.

Erdosteine was discovered and developed in Italy at Recipharm’s facility in Paderno Dugnano and is indicated for the treatment of acute and chronic respiratory diseases including Chronic Obstructive Pulmonary Disease (COPD).

Katherine Salessi Nia, Medical Manager for Erdosteine at Recipharm, commented: ”We have now been able to confirm the beneficial effects of Erdosteine in restoring the pulmonary functions also in patients affected by COVID-19. We are planning to develop further studies to investigate if the molecule can have a role in prophylaxis for this pandemic treatment.”

Mentioned Companies
Recipharm AB
View company profile